This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hoff, P. M. Articles by Pazdur, R. Search for Related Content PubMed PubMed Citation Articles by Hoff, P. M. Articles by Pazdur, R.

UFT Plus Oral Leucovorin: A New Oral Treatment for Colorectal Cancer

Division of Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Correspondence: Richard Pazdur, M.D., Division of Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 92, Houston, Texas 77030, USA. Telephone: 713-792-3634; Fax: 713-745-1827; e-mail: rpazdur{at}notes.mdacc.tmc.edu

UFT is an oral antineoplastic agent that combines the 5-fluorouracil (5-FU) prodrug tegafur with uracil in a 1:4 molar ratio. Uracil is added because it competitively inhibits the degradation of 5-FU, resulting in increased plasma and tumor 5-FU concentrations. Although UFT has been available in Japan since 1984, it has only recently been in clinical development in the United States. Beginning in 1991, phase I/II trials of UFT have been conducted in the United States to establish a maximum tolerated dose, evaluate its pharmacokinetics, and assess its efficacy and safety in advanced colorectal cancer. Pharmacokinetic studies demonstrated that UFT 300 mg/m²/day administered in divided doses every 8 h for 28 days provides an effective oral method of delivering a prolonged exposure to 5-FU. UFT plus oral leucovorin is well tolerated, with diarrhea as the dose-limiting toxicity. Unlike i.v. administered 5-FU, UFT is not associated with significant myelosuppression, mucositis, hand-foot syndrome, or alopecia, and patients have a decreased risk of toxicity-related hospitalization. In a phase II trial in advanced colorectal cancer, UFT plus oral leucovorin produced an objective response rate of 42%, with survival similar to weekly i.v. 5-FU plus leucovorin. The reduced toxicity, efficacy comparable to i.v. 5-FU, and the convenience and cost savings of an orally administered regimen have potential pharmacoeconomic advantages.

Key Words. Colorectal cancer • UFT • 5-fluorouracil • Tegafur • Uracil • Leucovorin

This article has been cited by other articles:

				M. Malet-Martino and R. Martino Clinical Studies of Three Oral Prodrugs of 5-Fluorouracil (Capecitabine, UFT, S-1): A Review Oncologist, August 1, 2002; 7(4): 288 - 323. [Abstract] [Full Text] [PDF]

				Chemotherapy for metastatic colorectal cancer DTB, July 1, 2002; 40(7): 49 - 52. [Abstract] [Full Text] [PDF]

				G. J. Peters, C. J. van Groeningen, G. Giaccone, and R. M. White Jr Fluorouracil (5FU) Pharmacokinetics in 5FU Prodrug Formulations With a Dihydropyrimidine Dehydrogenase Inhibitor J. Clin. Oncol., November 15, 2001; 19(22): 4267 - 4269. [Full Text]

				R.B. Arbuckle, S.L. Huber, and C. Zacker The Consequences of Diarrhea Occurring During Chemotherapy for Colorectal Cancer: A Retrospective Study Oncologist, June 1, 2000; 5(3): 250 - 259. [Abstract] [Full Text]